International journal of clinical practice
-
Int. J. Clin. Pract. · Aug 2013
Review Comparative StudyComplementary therapies in hemifacial spasm and comparison with other movement disorders.
We determined the prevalence, range and factors influencing the use of complementary therapy among hemifacial spasm patients and compared the patterns of use of complementary therapies across different movement disorders in a systematic pooled analysis of published literature. ⋯ Complementary therapies are used by over 50% of HFS patients, and the use is correlated with severity of disease. Despite differences in race, culture and population demographics, acupuncture and massage are used by patients across the spectrum of movement disorders.
-
Int. J. Clin. Pract. · Jul 2013
Comparative StudyMarkers of insulin resistance and carotid atherosclerosis. A comparison of the homeostasis model assessment and triglyceride glucose index.
The present investigation was designed to test the association between carotid atherosclerosis and two simple markers of insulin resistance, i.e. HOMA-Index and TyG-Index. ⋯ The present findings suggest that TyG-Index is better associated with carotid atherosclerosis than HOMA-IR.
-
Int. J. Clin. Pract. · Jul 2013
Comparative StudyMirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
To examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results. ⋯ The efficacy and safety of mirabegron are demonstrated in this large pooled clinical trial dataset in patients with OAB.
-
Int. J. Clin. Pract. · Jun 2013
Multicenter Study Observational StudyExtended-release niacin/laropiprant for lipid management: observational study in clinical practice.
Patients with dyslipidaemia or hypercholesterolemia carry a substantially increased cardiovascular risk and need optimal treatment of this key risk factor. We aimed to investigate the utilisation, efficacy and tolerability of the single pill combination extended-release niacin/laropiprant 1000 mg/20 mg or 2000 mg /40 mg under conditions of primary care practice. ⋯ Niacin/laropiprant resulted in beneficial effects on serum lipids and was generally well tolerated. The full potential of the drug combination was not explored by most physicians due to discontinuation of statins and lack of titration of the combination. Overall, treatment effects were consistent with those seen in controlled trials.